Biotech | February 10, 2022
Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
On track to complete the BLA submission in the first half of 2022
On track to complete the BLA submission in the first half of 2022
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles
The company will manufacture a cancer immunotherapy product from 2022
The platform’s technology works as a compression algorithm for molecular testing
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
Subscribe To Our Newsletter & Stay Updated
